Cargando...
Timing is everything in the treatment of multiple sclerosis
We present two similar cases of relapsing–remitting multiple sclerosis, both of whom received treatment with the monoclonal antibody alemtuzumab, but had significantly different long-term outcomes. Patient A is 12 years into his illness and was treated early in his disease course, he has no disabili...
Gardado en:
| Publicado en: | BMJ Case Rep |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BMJ Publishing Group
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4401937/ https://ncbi.nlm.nih.gov/pubmed/25878229 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2014-208960 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|